Module 4: From Signal to Strategy: Interpreting In Vivo Micronucleus and Comet Assay Results

Recorded On: 05/27/2027

image
image


This presentation focuses on the role of in vivo genetic toxicology assays within the nonclinical safety assessment of pharmaceuticals, with emphasis on in vivo micronucleus and in vivo comet assays. These assays are critical tools for evaluating clastogenic, aneugenic, and DNA‑damaging potential in the context of whole‑animal exposure and metabolism. The session reviews the scientific rationale, strengths, and limitations of each assay and discusses how positive findings are interpreted within a weight‑of‑evidence framework. Key topics include the ramifications of a positive in vivo result, strategies for confirmatory or follow‑up testing, and factors influencing assay selection, study design, and tissue targeting. Regulatory expectations and implications under relevant global guidance are addressed, including how in vivo data can impact development timelines, risk assessment, and regulatory decision making. The presentation concludes with a case study illustrating a practical approach to navigating a positive in vivo genetic toxicology finding, highlighting data integration, mechanistic considerations, communication with regulators, and potential paths forward. Participants will gain practical insights into applying these assays to support informed, science‑based decision making in drug development.

Wen Sun, PhD

Wen Sun, PhD

Director of Genetic Toxicology

Pfizer Inc.

Dr. Wen Sun is the director of the Genetic Toxicology department at Pfizer. She received her PhD in Molecular and Cellular Biology from the University of Iowa and worked as a postdoctoral researcher in the Pharmacology Department at Yale University prior to joining Pfizer seven years ago. Currently, Dr. Sun oversees all scientific and strategic development of genetox at Pfizer, provides subject-matter expertise, and guides teams and chemists away from genotoxicity liabilities. Dr. Sun leads numerous working groups within the Health and Environmental Sciences Institute, focusing on the use of NAM-based approaches in hazard ID and risk management. Dr. Sun has been a long-time member of GTA and currently serves on the board of directors of the Environmental Mutagenesis and Genomics Society.

Key:

Complete
Failed
Available
Locked
Module 4: From Signal to Strategy: Interpreting In Vivo Micronucleus and Comet Assay Results
Module 4: From Signal to Strategy: Interpreting In Vivo Micronucleus and Comet Assay Results, Wen Sun, PhD
Recorded 05/27/2027  |  90 minutes
Recorded 05/27/2027  |  90 minutes As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Survey
13 Questions
13 Questions ACT values your feedback. Please help us continue to provide high-quality educational offerings by completing this short survey. The survey will become available after you have met the minimum viewing requirement for the recording. Once you complete the survey, your certificate of completion will become available on your dashboard or for download.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Your certificate of completion will become available after you have met the minimum viewing requirement and completed the module survey.